DTIL Revenue Drops 99%
Precision BioSciences (NASDAQ:DTIL), a clinical-stage biotechnology firm focused on gene editing, released its Q2 FY2025 earnings results on August 7, 2025. The main headline: GAAP revenue dropped to $18 thousand, considerably underperforming the consensus GAAP estimate of $4.98 million, and falling well short of the prior year's $49.9 million in GAAP revenue. The revenue decline primarily reflected the wind-down of past collaboration revenue, and while significant progress was made on the company’s clinical pipeline, the company remains heavily reliant on new collaborations or milestone payments going forward.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Precision BioSciences (NASDAQ:DTIL) develops therapies using a proprietary gene editing platform, ARCUS. ARCUS is designed to edit genes in living organisms, tapping into homing endonuclease proteins that can be engineered for genetic precision and efficiency. This platform aims to tackle diseases with high unmet medical needs, such as chronic hepatitis B and Duchenne muscular dystrophy.
Source Fool.com